<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443481</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A2124</org_study_id>
    <secondary_id>2011-000103-41</secondary_id>
    <nct_id>NCT01443481</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function</brief_title>
  <official_title>A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open label study to assess pharmacokinetics (PK) of TKI258 at
      single-dose and steady state in adult cancer patients either with mild, moderate or severe
      hepatic impairment or with normal hepatic function. Hepatic function in study patients will
      be categorized as normal, mild, moderate or severe based upon pre-dose (Day 1) total
      bilirubin and AST/ALT levels. Starting dose of TKI258 will depend on total bilirubin and
      ALT/AST levels at baseline. Patients will be treated until disease progression (assessed by
      RECIST 1.1), unacceptable toxicity, death or discontinuation from the study treatment for any
      other reason.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter of Cmax following a single dose of TKI258 and at the steady state</measure>
    <time_frame>Day 1, Day 19</time_frame>
    <description>Cmax will be evaluated after a single dose of TKI258 and at the steady state following a 5 days on/2 days off dosing schedule. Cmax is the maximum (peak) plasma, blood, serum, or other body fluid drug concentration after a single dose administration (mass x volume - 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter of Tmax following a single dose of TKI258 and at the steady state</measure>
    <time_frame>Day 1, Day 19</time_frame>
    <description>Tmax will be evaluated after a single dose of TKI258 and at the steady state following a 5 days on/2 days off dosing schedule. Tmax is the time to to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after a single dose administration (mass x volume - 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter of AUClast following a single dose of TKI258 and at steady state</measure>
    <time_frame>Day 1, Day 19</time_frame>
    <description>AUClast will be evaluated after a single dose of TKI258 and at the steady state following a 5 days on/2 days off dosing schedule. AUC from time zero to the last measurable concentration sampling time t(last) (mass x time x volume^-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter of AUCinf following a single dose of TKI258</measure>
    <time_frame>Day 1, Day 19</time_frame>
    <description>AUCinf is the time to zero to infinity (mass x time x volume)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events and Serious Adverse Events as assessed by Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Baseline and every 4 weeks</time_frame>
    <description>The Common Terminology Criteria for Adverse Events (AE) is a descriptive terminology which can be utilized for AE reporting. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding),symptom, or disease temporally associated with the use of a treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vital Signs</measure>
    <time_frame>Baseline, Weeks 1, 4, 5, 9 and once every 8 weeks thereafter</time_frame>
    <description>Body temperature, sitting pulse rate, and sitting blood pressure will be measured at each visit. Blood Pressure (BP) will be measured according to the National Institute of Health, National Hart, Lung and Blood Institute Guidelines with following standardized techniques: patients are seated; BP measurement begins after at least 5 minutes of rest, the appropriate cuff size is used , measurements will be taken preferably with a mercury sphygmomanometer. If the BP reading is ≥ 160mm Hg systolic and/or ≥100 mmHg diastolic, repeat the measurement to verify initial reading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response to anti-tumor activity of TKI258 through imaging as per RECIST 1.1</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve (&quot;respond&quot;), stay the same (&quot;stable&quot;) or worsen (&quot;progression&quot;) during treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Electrocardiogram</measure>
    <time_frame>Baseline, Weeks 1, 4, 5</time_frame>
    <description>A standard 12 lead Electrocardiogram(ECG)will be used. In order for an accurate evaluation of baseline QTc, a total of three 12-lead ECGs will be performed within 72 hours prior to the first dose of TKI258 administration on Week 1, Day 1. All ECGs will be transmitted to a central laboratory and will be centrally reviewed by an independent reviewer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Hepatic Function Abnormalities</measure>
    <time_frame>Baseline, every 4 weeks</time_frame>
    <description>Exploration of the relationship between Pharmacokinetics (PK) and hepatic functional abnormalities (i.e. bilirubin, ALT/AST, and Child-Pugh classification using regression analysis as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>TKI258 normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI258 mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI258 moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI258 severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dovitinib</intervention_name>
    <description>Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups</description>
    <arm_group_label>TKI258 normal hepatic function</arm_group_label>
    <arm_group_label>TKI258 mild hepatic impairment</arm_group_label>
    <arm_group_label>TKI258 moderate hepatic impairment</arm_group_label>
    <arm_group_label>TKI258 severe hepatic impairment</arm_group_label>
    <other_name>TKI258</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed solid tumor, excluding breast
             cancer, that is either refractory to the standard therapy or has no available
             therapies.

          2. ECOG performance status (PS) 0 or 1

          3. Patients must have measurable and/or non-measurable lesion(s) as assessed by Computer
             Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) per RECIST 1.1

        Exclusion Criteria:

          1. Patients with known brain metastases.

          2. Patients who have undergone major surgery ≤ 4 weeks prior to starting study treatment

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles Dept. of UCLA (4)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center DUMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center SC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>5800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=13906</url>
    <description>Results for CTKI258A2124 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <keyword>hepatic impairment</keyword>
  <keyword>Child-Pugh classification</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>PK</keyword>
  <keyword>RECIST 1.1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

